Following scrutiny from Democratic senators in Congress, the US Federal Trade Commission has issued a policy statement on the proper listing of pharmaceutical patents.
The FTC argues that some drugmakers have failed to properly describe the reference drug or methods for their use, potentially stymying generics drugmakers who wish to develop off-patent versions once the defined period of exclusivity has come to an end.
Problems with the way patents are registered, a process that focuses on the comprehensive “Orange Book” of enforceable US patents for medicines, have been recognized for years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze